ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer-Reference-Cited by-同舟云学术

ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer

Published:2023-03 Issue:1 Volume:22 Page:92-99
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Reid Tony R.,Abrouk Nacer,Caroen Scott,Oronsky Bryan^ORCID,Stirn Meaghan,Larson Christopher,Beale Keola,Knox Susan J.,Fisher George

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference14 articles.

1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial;Yoshino;J Clin Oncol,2022

3. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study;Cremolini;Lancet Oncol,2015

4. Clinical relevance of microsatellite instability in colorectal cancer;de la Chapelle;J Clin Oncol,2010

5. Mechanisms of drug resistance in colon cancer and its therapeutic strategies;Hu;World J Gastroenterol,2016

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Cancer Antioxidant Regulation System in Therapeutic Resistance;Antioxidants;2024-06-27

2. Targeting Macrophage Polarization in Infectious Diseases: M1/M2 Functional Profiles, Immune Signaling and Microbial Virulence Factors;Immunological Investigations;2024-06-24

3. Targeting tumor-associated macrophages to reverse antitumor drug resistance;Aging;2024-05-23

4. Glioblastoma Phagocytic Cell Death: Balancing the Opportunities for Therapeutic Manipulation;Cells;2024-05-11

5. An “All‐In‐One” Immunomodulator‐Engineered Clinical Translatable Immunotherapy of Advanced Hepatocellular Carcinoma;Advanced Healthcare Materials;2024-04-03